Abstract 67P
Background
Inflammation is a key factor in the pathogenesis of sarcopenia, a negative prognostic factor in cancer. Higher neutrophil-to-lymphocyte ratio (NLR) is significantly associated with poorer overall survival (OS) across multiple tumor types and can serve as cost-effective surrogate biomarker of a preexisting inflammatory status. We aimed to assess the combined prognostic value of sarcopenia and NLR in IO-treated pt.
Methods
Retrospective analysis of pt with metastatic solid tumors treated with IO within the MP and the ME (off-label/expanded access use) programs at the Catalan Institute of Oncology between Jan’11-Dec’19. Included pt had clinic-analytical data and computed tomography scans performed as standard practice within a month before first IO dose. To analyze sarcopenia, skeletal mass index (SMI) was calculated using Slice-O-Matic software at L3 landmark and sarcopenia was dichotomized according to the median baseline SMI (high versus low). High NLR (>=3) versus low NLR (<3) was calculated in baseline IO-blood test. Kaplan-Meier was used to estimate median OS and log-rank test was used to compare survival curves.
Results
We included 90 pt: the majority were male (66%), <75 years (76%), ECOG <2 (89%), <2 sites of metastases (61%) and had received <3 lines of treatment (93%). Most common tumors were lung (37%) genitourinary (29%), skin (27%) and others (8%, including gynecological, gastrointestinal, sarcomas and SCCHN). Sarcopenia was detected in half of pt of whom 67% had high NLR. OS was 23.5 months (m) in high SMI/low NLR, 12.3m in high SMI/high NLR, 11.8m in low SMI/low NLR and 3 m in low SMI/high NLR groups (p=0.0003). Noteworthy, OS rate at 12 m was 75% (CI 95%; 60-94) in high SMI/low NLR group, whilst in low SMI/high NLR group was 27% (CI 95%; 15-48) (p=0.0001).
Conclusions
The combination of both widely accessible prognostic biomarkers may help in MP and ME programs decision-making, by identifying the subgroup of low SMI/high NLR patients with worse prognosis to better select candidates. Strategies for reducing systemic inflammation and improving skeletal muscle mass are warranted to increase benefits of IO.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
94P - Harnessing circulating tumor DNA in bronchoalveolar lavage fluid for precise molecular diagnosis of NSCLC
Presenter: Frank Borm
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Automatic data processing to identify EGFR mutations in pathology reports of patients with non-small cell lung cancer (NSCLC)
Presenter: Betzabel Cajiao Garcia
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in endometrial cancer (EC) patients
Presenter: Simona Duranti
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Prospects of liquid biopsy in determining prognosis in children with HGG and DIPG
Presenter: Olga Regentova
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Liquid biopsy in NSCLC: A promising tool to predict immunotherapy response
Presenter: Ana Fernández
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Comprehensive genomic sequencing as an ancillary diagnostic tool for pathologists
Presenter: Dan Miller
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Standard serum biomarkers to help predict a cancer diagnosis in patients with non-specific symptoms: Data from Guy´s rapid diagnostic clinic
Presenter: Maria Monroy Iglesias
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Patient-derived organoids to optimize CDK4/6 inhibitor-based treatment selection in early breast cancer
Presenter: Carla Alves
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - MicroRNAs in urine and saliva as non-invasive biomarkers of minimal residual disease in pediatric acute lymphoblastic leukemia
Presenter: Alejandra Pando-Caciano
Session: Cocktail & Poster Display session
Resources:
Abstract
103P - MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract